To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.

Patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks, with follow-up every 4 weeks through week 20.

Inclusion Criteria

Patients must have:

• Asymptomatic HIV-1 infection.
• CD4 count of 400-700 cells/mm3.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Significant illness.
• Acute illness at randomization.
• Hemodialysis.

Prior Medication:

Excluded:

• Antiretroviral use within 60 days prior to study entry.